Weekly subcutaneous injections of 2.4 mg semaglutide were administered to 902 obese or overweight patients with comorbidities. After a 20-week run-in period, 803 patients achieved the target dose of 2.4mg, and their average body weight decreased from 107.2kg to 96.1kg; subsequently, these...